Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Patient received 2nd dose of vaccine late; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 77-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included shingrix (Received 1st dose of vaccine in October 2022). On 31-AUG-2024, the patient received the 2nd dose of Shingrix. On 31-AUG-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Patient received 2nd dose of vaccine late). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 30-JAN-2025 Reporter called to ask if a male patient had received a first dose in October 2022 and second dose in august 2024, whether he would be ok with this schedule or if they need to revaccinate. Patient received 2nd dose of vaccine late, which led to Drug dose administration interval too long.